哮喘联盟

   摘要
   通过检测天然纯化过敏原或重组过敏原特异性IgE水平在分子水平确定哮喘患者致敏性可提高诊断的准确性并帮助哮喘疾病分型。由于某些标志物能反应种类特异性致敏作用并能从共致敏作用中解决交叉反应现象，使分子诊断得以应用。分子诊断的准确性均不如传统的过敏原筛检试验，但其检测结果可能最终影响临床医生对哮喘患者的个体化治疗措施的制定，包括减少目标过敏原暴露的指示以及选择合适的过敏原进行特异性免疫治疗以提高治疗的安全性和免疫治疗的有效性。虽然如此，由于变异原致敏性并不一定代表临床反应性，所有的体外试验均应经过临床病史验证。
 

（杨冬 审校）
Expert Rev Mol Diagn. 2015 Apr 12:1-11. [Epub ahead of print]
 

Molecular allergy diagnosis for the clinical characterization of asthma.
 

Sastre-Ibañez M1, Sastre J.

Author information
 

Abstract
Defining the allergen sensitization of a patient with asthma at the molecular level by measuring specific IgE to purified natural or recombinant allergens can improve diagnostic accuracy and improve asthma phenotyping. Molecular diagnosis is possible thanks to the specificity of some markers of species-specific sensitization and resolve cross-reactivity phenomena from a true co-sensitization. None of this precision is possible with conventional allergy tests, and such information will eventually give clinicians the possibility to individualize the actions taken, including indications on reducing targeted-allergen exposure or selection of suitable allergens for specific immunotherapy, thereby increasing the safety and efficacy of immunotherapy. Nevertheless, all in vitro tests should be assessed alongside clinical history, as allergen sensitization does not necessarily imply clinical responsiveness.
 

Expert Rev Mol Diagn. 2015 Apr 12:1-11. [Epub ahead of print]